InterVenn Biosciences Adds Alec Ford and Mitch Levine to Board of Directors

InterVenn Biosciences announced in a press release the appointment of Alec Ford and Mitch Levine to its Board of Directors. The company stated that the new board members will support its focus on advancing the commercialization of glycoproteomic diagnostics.

Alec Ford brings over three decades of experience in genomics, pharmaceuticals, and biotechnology. He currently serves as Chief Executive Officer of Karius, a company specializing in liquid biopsy for infectious diseases, and previously held senior roles at Myriad Genetics, Novartis, Sanofi-Aventis, Nektar Therapeutics, and Pfizer.

Mitch Levine, Chief Executive Officer of Prenostics, has extensive experience in finance and corporate strategy within the biotechnology and diagnostics sectors. He previously led SmartHealth Diagnostics and served as Chief Financial Officer at Oncocyte, where he managed multiple capital raises and acquisitions. Levine also holds board positions at several life sciences companies.

InterVenn applies artificial intelligence to analyze glycoproteins for disease detection and clinical insights. The company aims to bring glycoproteomics into clinical practice across areas such as women's health and oncology.